Immunosurveillance by evaluating anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the long immunity against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. The aim of this study was to evaluate the kinetics of antibody response in vaccine recipients. We measured anti-S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 1013 healthy individuals naïve to SARS-CoV2 infection after two and three COVID-19 vaccine doses. We found that anti-S-RBD IgG levels are higher in females than males. Antibody levels gradually decrease to a steady state after four months since the peak, and the decay is independent of age, sex, vaccine doses, and baseline antibodies titer. The third dose induces a high anti-S-RBD IgG reactivity in individuals with previous high responses and triggers a moderate-high anti-S-RBD IgG reactivity. The assessment of anti-S-RBD IgG levels is essential for monitoring long-term antibody response. A third SARS-CoV-2 vaccine dose is associated with a significant immunological response. Thus, our results support the efficacy of the vaccine programs and the usefulness of the third dose.

Lo Sasso, B., Agnello, L., Giglio, R.V., Gambino, C.M., Ciaccio, A.M., Vidali, M., et al. (2022). Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine. SCIENTIFIC REPORTS, 12(1), 1-7 [10.1038/s41598-022-12750-z].

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Lo Sasso, Bruna
Co-primo
;
Agnello, Luisa
Co-primo
;
Giglio, Rosaria Vincenza;Gambino, Caterina Maria;Ciaccio, Anna Maria;Ciaccio, Marcello
Ultimo
2022-12

Abstract

Immunosurveillance by evaluating anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the long immunity against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. The aim of this study was to evaluate the kinetics of antibody response in vaccine recipients. We measured anti-S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 1013 healthy individuals naïve to SARS-CoV2 infection after two and three COVID-19 vaccine doses. We found that anti-S-RBD IgG levels are higher in females than males. Antibody levels gradually decrease to a steady state after four months since the peak, and the decay is independent of age, sex, vaccine doses, and baseline antibodies titer. The third dose induces a high anti-S-RBD IgG reactivity in individuals with previous high responses and triggers a moderate-high anti-S-RBD IgG reactivity. The assessment of anti-S-RBD IgG levels is essential for monitoring long-term antibody response. A third SARS-CoV-2 vaccine dose is associated with a significant immunological response. Thus, our results support the efficacy of the vaccine programs and the usefulness of the third dose.
Settore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinica
https://doi.org/10.1038/s41598-022-12750-z
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126106/pdf/41598_2022_Article_12750.pdf
Lo Sasso, B., Agnello, L., Giglio, R.V., Gambino, C.M., Ciaccio, A.M., Vidali, M., et al. (2022). Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine. SCIENTIFIC REPORTS, 12(1), 1-7 [10.1038/s41598-022-12750-z].
File in questo prodotto:
File Dimensione Formato  
Longitudinal analysis of anti‐SARS‐CoV‐2 S‐RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine.pdf

accesso aperto

Descrizione: Articolo
Tipologia: Versione Editoriale
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/567472
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact